Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea

著者: Selam Mihreteab, Lucien Platon, Araia Berhane, Barbara H. Stokes, Marian Warsame, Pascal Campagne, Alexis Criscuolo, Laurence Ma, Nathalie Petiot, Cécile Doderer-Lang, Eric Legrand, Kurt E. Ward, A Kassahun, Pascal Ringwald, David A. Fidock, Didier Ménard - New England Journal of Medicine, NEJM 2023 被引用: 203

BACKGROUND: on the continent is troubling, given the lack of alternative treatments. METHODS: that result in variable performance of histidine rich protein 2 (HRP2)-based rapid diagnostic tests for malaria. RESULTS: R622I mutation, which made them potentially undetectable by HRP2-based rapid diagnostic tests. CONCLUSIONS: in Eritrea threaten to compromise regional malaria control and elimination campaigns. (Funded by the Bill and Melinda Gates Foundation and others; Australian New Zealand Clinical Trials Registry numbers, ACTRN12618001223224, ACTRN12618000353291, and ACTRN12619000859189.).